FDA approves Epclusa for chronic Hepatitis C.

The combination drug Epclusa has been approved by the United States Food and Drug Administration to treat six major strains of chronic Hepatitis C virus (HCV).

The FDA revealed that Epclusa was evaluated in clinical trials involving more than 1,500 people, 99 percent of the participants given the drugs had no virus detected in the blood, 12 weeks after.

No Comments

Leave a Comment